Trials / Unknown
UnknownNCT04056572
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Patients With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3139 | TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS. |
Timeline
- Start date
- 2019-08-13
- Primary completion
- 2021-10-30
- Completion
- 2022-04-30
- First posted
- 2019-08-14
- Last updated
- 2019-10-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04056572. Inclusion in this directory is not an endorsement.